Synthesis of Symmetrical Tetrameric

Conjugates of the Radiolanthanide

Chelator DOTPI for Application in

Endoradiotherapy by Means of Click

Chemistry by Wurzer, Alexander et al.
ORIGINAL RESEARCH
published: 10 April 2018
doi: 10.3389/fchem.2018.00107
Frontiers in Chemistry | www.frontiersin.org 1 April 2018 | Volume 6 | Article 107
Edited by:
Lorenzo Tei,
Università degli Studi del Piemonte
Orientale, Italy
Reviewed by:
Steve J. Archibald,
University of Hull, United Kingdom
Kristina Djanashvili,
Delft University of Technology,
Netherlands
*Correspondence:
Johannes Notni
johannes.notni@tum.de
†These authors have contributed
equally to this work.
‡Present Address:
Adrienn Vágner,
Scanomed Ltd., Debrecen, Hungary
Specialty section:
This article was submitted to
Inorganic Chemistry,
a section of the journal
Frontiers in Chemistry
Received: 24 January 2018
Accepted: 22 March 2018
Published: 10 April 2018
Citation:
Wurzer A, Vágner A, Horváth D,
Fellegi F, Wester H-J, Kálmán FK and
Notni J (2018) Synthesis of
Symmetrical Tetrameric Conjugates of
the Radiolanthanide Chelator DOTPI
for Application in Endoradiotherapy by
Means of Click Chemistry.
Front. Chem. 6:107.
doi: 10.3389/fchem.2018.00107
Synthesis of Symmetrical Tetrameric
Conjugates of the Radiolanthanide
Chelator DOTPI for Application in
Endoradiotherapy by Means of Click
Chemistry
Alexander Wurzer 1†, Adrienn Vágner 2†‡, Dávid Horváth 2, Flóra Fellegi 2,
Hans-Jürgen Wester 1, Ferenc K. Kálmán 2 and Johannes Notni 1*
1 Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany, 2Department of Inorganic and
Analytical Chemistry, University of Debrecen, Debrecen, Hungary
Due to its 4 carbonic acid groups being available for bioconjugation, the cyclen
tetraphosphinate chelator DOTPI, 1,4,7,10-tetraazacyclododecane-1,4,7,
10-tetrakis[methylene(2-carboxyethylphosphinic acid)], represents an ideal scaffold
for synthesis of tetrameric bioconjugates for labeling with radiolanthanides, to be
applied as endoradiotherapeuticals. We optimized a protocol for bio-orthogonal
DOTPI conjugation via Cu(I)-catalyzed Huisgen-cycloaddition of terminal azides
and alkynes (CuAAC), based on the building block DOTPI(azide)4. A detailed
investigation of kinetic properties of Cu(II)-DOTPI complexes aimed at optimization
of removal of DOTPI-bound copper by transchelation. Protonation and equilibrium
properties of Ca(II)-, Zn(II), and Cu(II)-complexes of DOTPI and its tetra-cyclohexylamide
DOTPI(Chx)4 (a model for DOTPI conjugates) as well as kinetic inertness (transchelation
challenge in the presence of 20 to 40-fold excess of EDTA) were investigated by
pH-potentiometry and spectrophotometry. Similar stability constants of CaII-, ZnII, and
CuII-complexes of DOTPI (logK(CaL) = 8.65, logK(ZnL = 15.40, logK(CuL) = 20.30)
and DOTPI(Chx)4 (logK(CaL) = 8.99, logK(ZnL) = 15.13, logK(CuL) = 20.42) were
found. Transchelation of Cu(II)-complexes occurs via proton-assisted dissociation,
whereafter released Cu(II) is scavenged by EDTA. The corresponding dissociation
rates [kd = 25 × 10
−7 and 5 × 10−7 s−1 for Cu(DOTPI) and Cu(DOTPI(Chx)4),
respectively, at pH 4 and 298K] indicate that conjugation increases the kinetic
inertness by a factor of 5. However, demetallation is completed within 4.5 and
7.2 h at pH 2 and 25◦C, respectively, indicating that Cu(II) removal after formation
of CuAAC can be achieved in an uncomplicated manner by addition of excess
H4EDTA. For proof-of-principle, tetrameric DOTPI conjugates of the prostate-specific
membrane antigen (PSMA) targeting motif Lys-urea-Glu (KuE) were synthesized via
CuAAC as well as dibenzo-azacyclooctine (DBCO) based, strain-promoted click
chemistry (SPAAC), which were labeled with Lu-177 and subsequently evaluated
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in vitro and in SCID mice bearing subcutaneous LNCaP tumor (PSMA+ human prostate
carcinoma) xenografts. High affinities (3.4 and 1.4 nM, respectively) and persistent tumor
uptakes (approx. 3.5% 24h after injection) confirm suitability of DOTPI-based tetramers
for application in targeted radionuclide therapy.
Keywords: Huisgen-reaction, potentiometry, spectrophotometry, phosphinate, radiopharmaceuticals,
endoradiotherapy, prostate-specific membrane antigen, theranostics
INTRODUCTION
Endoradiotherapy (also termed molecular radiotherapy,
radioligand therapy or, if addressing peptide receptors, peptide
receptor radionuclide therapy (PRRT) or, if involving alpha-
emitting nuclides, targeted alpha therapy) (Oyen et al.,
2007) refers to the internal application of radionuclides for
therapeutic purposes, above all, for curing cancer. In the
respective disease management schemes, radiotherapeutics
represent the natural complements to imaging tracers. In
a tandem application of both types of agents, referred to
as “theranostics,” one targeting mechanism is exploited
for delivery of different sorts of radionuclides to tissues,
either for diagnostic purposes, that is, with the intention to
localize lesions by means of external detection of emitted
gamma photons, or to achieve a therapeutic effect via
local absorption of particle (i.e., alpha- or beta) radiation.
The corresponding radiopharmaceuticals are frequently
based on peptides, peptidomimetics, enzyme inhibitors,
or similar molecules capable of recognizing a specific cell
surface receptor, membrane-bound enzyme, ion channel, or
comparable target. The bioactive structures are often decorated
with a chelate ligand for kinetically inert complexation of
a metal ion radionuclide (Wadas et al., 2010). At present,
radiotherapeutics most frequently rely on lanthanide(III)- or
chemically related ions, such as 177Lu, 90Y, 225Ac, or 213Bi
(Notni and Wester, 2018). Recognizing malignant cells by
overexpression of above-mentioned surface markers, the
radiolabeled bioconjugates deliver these beta- or alpha-emitting
isotopes in the lesion, resulting in a local irradiation which kills
malignant cells.
In this context, the chelator DOTA (Figure 1) plays an
important role (Stasiuk and Long, 2013) since it forms stable
and sufficiently inert complexes with virtually all relevant metal
ions. DOTA is usually attached to e.g., peptides via amide
formation on one side arm, resulting in derivatives of DOTA-
monoamide which is the actual chelator structure in such
conjugates (commonly dubbed “DOTA peptides”). However, a
likewise functionalization of more than one acetic acid side arm
of DOTA yields conjugates whose metal complexes either lack
kinetic inertness (e.g., in case of the positron emitter 68GaIII) or
show very slow formation kinetics (namely, with lanthanide(III)
ions) (Baranyai et al., 2007; Pasha et al., 2007), limiting practical
applicability in radiopharmacy. Conjugates comprising more
than one biomolecule (multimers) are nevertheless desirable
because a multitude of similar bioactive structure elements
in a single framework usually results in enhanced target
affinities, and sometimes increases uptake of the respective
radiolabeled compounds in target tissues (Maschauer et al.,
2017).
For this purpose, we recently designed the DOTA-analog
tetraphosphinate chelator DOTPI (Figure 1) featuring
four terminal carboxylic acid moieties, which are not
required for metal ion complexation and, therefore, are
available for bioconjugation (Šimecˇek et al., 2013). However,
similar to the observations made for its smaller congener
TRAP (1,4,7-triazacyclononane-1,4,7-tris[methylene(2-
carboxyethylphosphinic acid)]) (Notni et al., 2014), amide
functionalization of these carboxylates using standard peptide
coupling reagents is sometimes complicated by instability of the
active ester intermediates (Baranyai et al., 2015). Similar to TRAP,
functionalization of DOTPI via “click chemistry,” (CuI-catalyzed
alkyne-azide cycloaddition, CuAAC) (Meldal and Tornøe,
2008) employing respective DOTPI-derivatives decorated with
“clickable” functional groups, such as DOTPI(azide)4 (Figure 1)
(Wurzer et al., 2018), appeared to be a valuable alternative.
Since the presence of ionic Cu inevitably results in copper
complexes of the desired conjugates wherein the Cu ion blocks
the coordination site intended for accommodation of the
radiometal, removal of chelator-bound Cu, ultimately being
transformed to oxidation state +2 during workup, is mandatory
to restore the radiolabeling properties. As discussed previously,
demetalation with sulfide or cyanide frequently causes problems,
while proton-assisted dissociation, promoted by excess of a
competing chelator, should be widely applicable and compatible
with many synthetic tasks (Notni andWester, 2016). Against this
background, we investigated the metal coordination properties
of DOTPI and a model conjugate thereof, DOTPI(Chx)4
(Figure 1), with a particular emphasis on CuII complexes, in
order to facilitate optimization of respective demetallation
protocols and to support application of CuAAC for elaboration
of DOTPI-based multimers.
RESULTS
In order to enhance legibility, charge, and protonation
state of ligands and complexes is indicated only where
necessary for comprehension and where possible without
ambiguity, e.g., in case it is referred to a single, well
defined species and not to a mixture, as is mostly the case
due to protonation equilibria. The animal experiments
were conducted in accordance with the German Animal
Welfare Act (Tierschutzgesetz), and an ethics approval was
obtained from the responsible authority (Regierung von
Oberbayern).
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FIGURE 1 | Structures of chelate ligands discussed in the text.
Solution Thermodynamics
Protonation schemes of cyclens bearing four N-substitutents
with additional donors (often referred to as DOTA-like ligands)
have been thoroughly investigated in the past (Desreux et al.,
1981; Bianchi et al., 2000; Takács et al., 2014). Table 1 displays
the respective data for DOTPI in comparison to DOTA (Baranyai
et al., 2010) and the most closely related tetraphosphinate
analogs, DOTPH (Bazakas and Lukeš, 1995; Kotková et al.,
2009) and DOTPEt (Lázár et al., 1991) (Figure 1). According
to previous literature, it is assumed that the first and second
protonation of all chelators under investigation occur at two
opposite ring nitrogen atoms. The subsequent protonation
steps most likely take place at protonation sites located at
the side arms (if available, at the carboxylate groups), due
to greater charge separation and lower electrostatic repulsion
between the distant protonated donor atoms. Protonations
of the phosphinate moieties, characterized by the logKH7 and
logKH8 for DOTPI and logK
H
3 for DOTPI(Chx)4, occur only
in the acidic pH region (Rohovec et al., 2000), which is
why these phosphinate ligands are generally capable of metal
complexation and rapid radiolabeling at much lower pH
values than chelators with acetic acid side arms, such as
DOTA.
The equilibrium properties of chelates based on the 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphinic
acid) scaffold depend on the electronic properties of the
substituents on the phosphorus atoms (Kotková et al., 2009).
logKH1 and logK
H
2 values for DOTPI(Chx)4 are somewhat
lower than those of DOTPI, while this lower basicity of the
ring nitrogens might be explained by the presence of the
more electronegative amide substituents on the pendant arms.
However, the lower logKH1 value measured for DOTA in 0.15M
NaCl has another reason; it is explained by the formation of
relatively stable [Na(DOTA)]3− complex (logKNaL = 4.38)
(Chaves et al., 1992). Our data indicate that DOTPI forms a
similar NaL complex, entailing a lower logKH1 value in presence
of 0.15M NaCl than in 0.1MMe4NCl (Šimecˇek et al., 2013).
Total basicity of ligands (6logKHi , Table 1) generally
correlates with thermodynamic stability constants (KML) of
their metal complexes, while in order to obtain chemically
meaningful values, the logKHi values of the distant carboxylate
groups were not considered for calculation of 6logKHi value of
DOTPI because they are not involved in metal ion coordination.
That being said, it is not surprising that the logKML value
of [Ca(DOTA)], [Zn(DOTA)], and [Cu(DOTA)] complexes
is about 2–5 logK unit higher than phosphinic acid analogs,
because DOTA shows a significantly higher total basicity
(Table 2).
Among the tetraphosphinates, total basicities 6logKHi of
DOTPI(Chx)4, DOTPI, and DOTPEt ligands are similar but
about 1–3 orders of magnitude higher than that of DOTPH
which, as expected, is reflected by similar logKCuL and logKZnL
values for CuII and ZnII complexes of the P-substitued
ligands but somewhat lower stabilities for those of DOTPH.
Thermodynamic stabilities of the CaII complexes are, however,
similar for all phosphinate ligands. This might be explained
by differences in the preferred coordination number of these
divalent metal ions (CuII and ZnII: 6, CaII: 6–8) owing to their
different size (CuII: 73 p.m., ZnII: 74 p.m., CaII: 100 p.m.),
entailing different structures for CuII and ZnII complexes as
observed for CaII complexes. Based on available structural data
(Riesen et al., 1986), it is assumed that the smaller cations are
bound in an N4O2 coordination environment involving only
two side arm oxygens, whereas CaII is surrounded by a N4O4
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TABLE 1 | Protonation constants of DOTPI(Chx)4, DOTPI, DOTP
H, DOTPEt, and DOTA at 25◦C (for structures see Figure 1).
DOTPI(Chx)4 DOTPI DOTP
H DOTPEt DOTA
I 0.15M NaCl 0.15M NaCl 0.1M Me4NCl
(Šimecˇek et al., 2013)
0.1M KNO3 0.1M KNO3 0.15M NaCl
logKH1 9.89 (1) 10.27 (1) 11.58 10.41, 10.58 10.94 9.14
logKH2 7.73 (1) 8.42 (1) 8.90 6.83, 6.93 8.24 9.21
logKH3 3.34 (1) 5.45 (2) 5.65 1.97, 1.90 3.71 4.48
logKH4 – 4.78 (2) 4.98 – – 4.03
logKH5 – 4.42 (2) 4.61 – – 1.99
logKH6 – 3.88 (2) 4.07 – – 1.58
logKH7 – 2.83 (2) 3.12 – – –
logKH8 – 1.17 (2) 1.31 – – –
6logKHi 20.96 22.69 24.91 19.21, 19.41 22.89 30.43
Equivalent protonations, occuring for DOTPI and DOTPI(Chx)4 at the first and second phosphinate oxygen, are denoted by logK
H
7 /logK
H
8 and logK
H
3 /logK
H
4 , respectively.
TABLE 2 | Stability constants (logKML ) for non-protonated DOTPI(Chx)4, DOTPI, DOTP
H, DOTPEt, and DOTA complexes formed with divalent metals at 25◦C,
determined by UV/Vis spectroscopy (a) or potentiometry (b).
DOTPI (Chx)4 DOTPI DOTP
H
(Baranyai et al., 2007)
DOTPEt
(Desreuxet al., 1981)
DOTA
(Takács et al., 2014)
I 0.15M NaCl 0.15M NaCl 0.1M Me4NCl
(Lázár et al., 1991)
0.1M KNO3 0.1M KNO3 0.15M NaCl
CuL 20.42 (1)a 20.30 (5)a 23.11 18.03 19.59 21.97 (1)
ZnL 15.13 (1)b 15.40 (2)b 18.57 14.60 15.80 17.35 (1)
CaL 8.99 (2)b 8.65 (3)b 12.48 9.46 9.39 13.84 (1)
Stepwise protonation constants of the complexes as well as details on experimental procedures and UV/VIS signals used for calculation are given in the Supplementary Information.
donor set involving all side arms. Hence, side arm basicity and
protonation presumably affects the complexation equilibria in a
different manner.
Formation of several protonated Cu(HxL) species at
pH < 7 has been confirmed by pH-potentiometric and
spectrophotometric studies of solutions containing CuII and
DOTPI(Chx)4 or DOTPI, respectively, while both ligands form
CuII complexes already in acidic solution (pH 1.5 and lower).
Since molar absorptivities of the protonated Cu(HxDOTPI)
and non-protonated Cu(DOTPI) species were found to be
essentially equal, it can be assumed that stepwise protonation
of Cu(DOTPI) starts with the non-coordinating carboxylates,
resulting in Cu(HL), Cu(H2L), Cu(H3L), and Cu(H4L). Two
further protonations at comparable pH are observed for CuII
complexes of both DOTPI(Chx)4 and DOTPI, while it appears
most plausible that they occur on phosphinate oxygens because
two of these moieties do not coordinate to CuII and can thus be
protonated.
Kinetic Inertness and Transchelation
In order to provide the necessary information for optimization
of demetallation protocols, we investigated the pH-dependent
kinetics of the transchelation of CuII from CuDOTPI and
CuDOTPI(Chx)4 complexes to ethylenediamine-tetraacetic acid
(EDTA). Reactions were monitored by UV spectrophotometry at
the absorption bands of Cu(DOTPI) and Cu(DOTPI(Chx)4) over
a pH range of 1.5–4.5, using a 20- and 40-fold excess of EDTA (see
Supplementary information).
FIGURE 2 | Pseudo-first-order rate constants at 25◦C in 0.15M NaCl for the
reaction of CuII complexes of DOTPI (empty symbols) and DOTPI(Chx)4 (filled
symbols) with a 20- (red) and 40-fold (green) excess of EDTA at different pH
values. Respective kd functions were calculated from kinetic and equilibrium
data.
Figure 2 shows that the obtained pseudo-first-order rate
constants do not depend on the excess of EDTA, and increase
with decreasing pH. Hence, it can be assumed that the
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TABLE 3 | Rate constants (kCu(HiL)) and half-lives (t½ = ln2/kd) characterizing the dissociation reactions of Cu(DOTPI) and Cu(DOTPI(Chx)4) complexes (0.15M NaCl,
25◦C).
Cu(DOTPI) Cu(DOTPI(Chx)4) Cu(TRAP)
(Baranyai et al., 2015)
Cu(TRAP(Chx)3)
(Baranyai et al., 2015)
kCuL (s
−1) – – – 6 × 10−7
kCu(HL) (s
−1) – (1.7 ± 0.3) × 10−5 – 2.3 × 10−3
kCu(H2L) (s
−1) – (2.9 ± 0.4) × 10−3 5 × 10−6 –
kCu(H3L) (s
−1) (1.0 ± 0.5) × 10−6 – 6.7 × 10−5 –
kCu(H4L) (s
−1) (3.1 ± 0.6) × 10−6 – 2.1 × 10−3 –
kCu(H5L) (s
−1) (4.6 ± 0.5) × 10−5 – – –
kCu(H6L) (s
−1) (2.0 ± 0.2) × 10−3 (KCu(H6L) = 17 ± 8) – – –
kd (h
−1) at pH = 3.0 5.0 × 10−2 3.1 × 10−2 4.4 × 10−1 2.4 × 10−1
t½ (h) at pH = 3.0 13.8 22.4 1.57 2.94
Literature data for corresponding TRAP complexes (Baranyai et al., 2015) are included for comparison.
transchelation of Cu(DOTPI) and Cu(DOTPI(Chx)4) occurs
by initial protonation, followed by spontaneous dissociation
of the protonated CuII complexes as rate-determining step,
while irreversibility is granted by scavenging the released CuII
with EDTA. Similar data and mechanistic implications have
been found for CuII complexes of the smaller triphosphinate
macrocycle TRAP (Baranyai et al., 2015), underscoring wide
applicability of the transchelation approach for demetallation of
chelator conjugates after CuAAC coupling (Notni and Wester,
2016).
Table 3 summarizes rate (k) and equilibrium constants (K)
of all possible pathways for dissociation of the protonated
species Cu(HxDOTPI) and Cu(HyDOTPI(Chx)4) (x = 3,4,5,6;
y = 1,2; for details see Supplementary Information). According
to the proposed mechanism, that is, a fast protonation
equilibrium followed by a first-order dissociation reaction
rendered irreversible by competitor excess, cleavage of the
protonated Cu(HxL) complex is promoted by transfer of the
proton, which is initially located on the pendant arm, to a ring
nitrogen, resulting in the most labile intermediate, an off-cage
complex (Baranyai et al., 2015). Overall, the proton displaces the
CuII ion from the coordination cage, causing dissociation of the
Cu(HxL) complex.
A comparison of the rate constants (kCu(HiL)) obtained for
protonated species Cu(HxDOTPI) and Cu(HyDOTPI(Chx)4)
confirms that dissociation of the uncharged species,
[Cu(H2DOTPI(Chx)4)] and [Cu(H6DOTPI)], which
likely contains two non-coordinated and protonated
phosphinic oxygen atoms, occurs with a very similar
rate. Moreover, the dissociation rates of [Cu(H6DOTPI)]
and [Cu(H2DOTPI(Chx)4)] are very similar to those of
[Cu(H4TRAP)] and [Cu(HTRAP(Chx)3)] (Baranyai et al., 2015),
which might be explained by similar activation parameters
characterizing the proton transfer process from the phosphinate
oxygen to the ring nitrogen, resulting in comparable dissociation
rate constants at pH< 2.
Figure 3 shows the calculated contributions of individual
dissociation rates for all protonated Cu(HxDOTPI) and
Cu(HyDOTPI(Chx)4) species to the overall demetallation
FIGURE 3 | Contributions of Cu(DOTPI) and Cu(DOTPI(Chx)4) complexes in
different protonation states to the overall rates of the dissociation reaction.
rates (see also Figures S3, S6), which decrease with increasing
pH. In the pH range 1.5–4.5, dissociation of Cu(DOTPI) and
Cu(DOTPI(Chx)4) occurs by the decomplexation of the various
protonated species, respectively. In this respect, [Cu(H6DOTPI)]
and [Cu(H2DOTPI(Chx)4)] are equivalent as they both carry
two phosphinate-bound protons and hence, show similar
dissociation rates. Since these species are prevailing at pH < 2,
they govern overall dissociation rates which are, therefore, nearly
identical (see also Figure 2). On the other hand, at pH > 4, a
substantial amount of protonated (and thus, labile) species is
observed only for the Cu(DOTPI) system, explaining the higher
inertness of Cu(DOTPI(Chx)4) complexes.
Figure 4 displays the quintessence of the kinetic studies for
practical consideration, namely, the dissociation half-lives (t½)
of Cu(DOTPI) and Cu(DOTPI(Chx)4) as functions of pH (see
Supplemental information, Equation 18). It shows that loss
of protonable carboxylates by amide functionalization results
in higher t½ of the respective Cu(DOTPI(Chx)4) complexes
at higher pH; at pH > 4, the increase exceeds one order of
magnitude. On the other hand, CuII removal from both neat
and decorated DOTPI occurs with similar efficiency at lower
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pH. In view of the calculated t½, it appears recommendable
to carry out such reactions at pH values below 3, preferably
at pH = 2, while slightly elevated temperature (e.g., 50◦C)
will also substantially accelerate the reaction (Baranyai et al.,
2015). Apart from that, a t½ of > 4,000 h for dissociation of
Cu(DOTPI(Chx)4) at pH > 5 suggests compatibility with the
positron emitter 64Cu (T½ = 12.7 h) for application in
64Cu-PET
imaging.
FIGURE 4 | Dissociation half lives (t½ = ln2/kd) of Cu(DOTPI) and
Cu(DOTPI(Chx)4) as functions of pH (25
◦C, 0.15M NaCl).
Application
In order to demonstrate utility of the CuAAC/demetallation
tandem reaction for assembly of large multimeric
bioconjugates and application in the design of therapeutic
radiopharmaceuticals, the 4-fold azide-decorated building
block DOTPI(azide)4 (Wurzer et al., 2018) was reacted
with alkyne-functionalized KuE (lysine-urea-glutamic acid,
an inhibitor motif for prostate-specific membrane antigen,
PSMA, EC 3.4.17.21; synonyms: glutamate carboxypeptidase
II, NAALADase (Mesters et al., 2006); a membrane-bound
zinc hydrolase which is overexpressed by malignant human
prostate cancers). As an alternative, the inhibitor was equipped
with dibenzo-azacyclooctyne (DBCO) (Agard et al., 2004) for
conjugation via “copper-free click chemistry” (strain-promoted
alkyne-azide cycloaddition, SPAAC) according to path B
in Figure 5. Although this approach circumvents the entire
demetallation problem, potentially obviating the above study,
the disadvantages of SPAAC are limiting its practical value in
the present context. Firstly, reaction rates for SPAAC are several
orders of magnitude lower than those of CuAAC, requiring
adjustment of reaction conditions, for example, a higher excess
of reactants, in order to achieve reasonable yields. Secondly,
the isomerism of the formed linker moiety gives rise to a total
of 6 stereoisomers of DOTPI(DBCO-KuE)4 which are hard to
separate, if at all. While the isomers are not likely to exhibit
noticeable differences regarding their pharmacodynamics,
justifying use of the mixture for in-vivo application, such
action might nonetheless lead to regulatory issues upon clinical
translation. Third, introduction of several large, non-polar
linker groups usually affects pharmacokinetics, above all, due to
FIGURE 5 | Synthesis of symmetrical tetrameric prostate-specific membrane antigen (PSMA) inhibitor conjugates via DBCO-driven, strain-promoted (SPAAC, path A),
or CuI-catalyzed (CuAAC, path B) alkyne-azide cycloaddition (Huisgen-reaction).
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increased plasma protein binding. The overall simplicity of the
CuAAC/demetallation approach (Figure 5, path A) thus appears
preferable for this type of synthetic task, not least because of
the known robustness and pharmacokinetic inertness of the
1,3-triazole linkage (Horne et al., 2004, 2009; Bock et al., 2007;
Liu et al., 2008; Pedersen and Abell, 2011; Davis et al., 2012;
Tischler et al., 2012).
Because the 177Lu-labeled tetramers feature nearly identical
linker lengths and differ only in the type of linkage, the
effect of the dibenzo-azacyclooctane system annulated to the
triazole moiety becomes clearly apparent. While PSMA affinities
of both tetramers are, as expected (Maschauer et al., 2017),
higher than that of clinically applied monomers (Weineisen
et al., 2014; Benešová et al., 2016), it is conspicuous that
the natLu-DOTPI(DBCO-KuE)4 exhibits a higher affinity than
natLu-DOTPI(Trz-KuE)4 which is featuring simple 1,2,3-triazole
linkages (IC50 = 1.4 ± 0.5 vs. 3.4 ± 0.1, respectively). This
is because apart from the primary KuE binding site, namely,
the catalytic center which contains two hydroxo-bridged ZnII
ions, the enzyme PSMA features another hydrophobic site in
close proximity (Zhang et al., 2010) which can be addressed by
lipophilic groups in the linker (Kularatne et al., 2009; Banerjee
et al., 2010). With regard to the DBCOmoieties, a virtue is hence
made of necessity, because these hydrophobic structure elements
contribute to a divalent binding mode. Since the observed
increase of affinity is linked to the particular combination of
binding sites of the target PSMA, this favorable effect of DBCO
cannot be generalized.
Apart from that, Figure 6 shows that the higher degree of
hydrophilicity of 177Lu-DOTPI(Trz-KuE)4 (logD = −5.0 ±
0.1) results in a remarkably low kidney uptake and a much
faster washout from non-target tissues as compared to 177Lu-
DOTPI(DBCO-KuE)4 (logD = −4.0 ± 0.1). A virtually similar
tumor uptake of both compounds after 24 h gives rise to
substantially better tumor-to-organ ratios for 177Lu-DOTPI(Trz-
KuE)4. However, although the acquired data are sufficient for
proof-of-principle in the context of this study, a more detailed
investigation of the compounds is necessary in order to draw a
reliable conclusion regarding their clinical potential.
DISCUSSION
Replacement of the acetate with amide groups in the pendant
arms of DOTPI does not affect the thermodynamic stability
(logKML values) of the CaII-, ZnII-, and CuII-complexes, while
dissociation half-lives of the CuII chelates at pH> 3 show a clear
trend toward higher kinetic inertness. This is another example for
the notion that thermodynamic stability constants of complexes
do not necessarily correlate with their kinetic inertness, requiring
more than just equilibrium data for prediction or confirmation of
the suitability of (radio-)metal chelates for in-vivo applications.
This applies even more because any data acquired under ideal
conditions, e.g., in neat solvents or well-defined buffers, should
be treated with care in view of a limited transferability to more
complex systems, such as living organisms. For example, the
aforementioned demetallation half-life of more than 4,000 h
FIGURE 6 | Biodistribution (Top) and tumor-to-organ ratios (Bottom) for
177Lu-DOTPI(DBCO-KuE)4 and
177Lu-DOTPI(Trz-KuE)4 (1.1–4.5 MBq,
0.11–0.15 nmol, n = 3), determined 1 and 24 h post injection in SCID mice
bearing subcutaneous LNCaP (PSMA-expressing human prostate carcinoma)
xenografts.
for Cu(DOTPI(Chx)4) at pH > 5 is no ultimate proof that
such conjugates are indeed applicable for 64Cu-PET imaging,
because other mechanisms than proton-assisted dissociationmay
contribute to in-vivo loss of 64Cu, even from highly stable and
inert chelates (Bass et al., 2000; Zarschler et al., 2014). A final
conclusion on this matter cannot be drawn without further
evidence and an in-vivo proof of concept, which however is
beyond the focus of this study.
CONCLUSION
A sufficiently low kinetic inertness of CuII complexes of
amide-functionalized DOTPI derivatives at low pH warrants
the practical applicability of the CuAAC/demetallation tandem
protocol, which can be conveniently conducted as a one-
pot reaction, for the synthesis of symmetrical tetrameric
DOTPI conjugates. In view of the inherent limitations of
Frontiers in Chemistry | www.frontiersin.org 7 April 2018 | Volume 6 | Article 107
Wurzer et al. DOTPI Conjugates Synthesized by CuAAC
strain-promoted AAC, such as slower reaction kinetics
and isomerism/lipophilicity of linkages, CuAAC appears
to be the preferable method for this purpose. A pilot in-
vivo study showed that the DOTPI-based PSMA-targeted
radiotherapeutics combine high affinity with excellent clearance
from non-target tissues, thus demonstrating the potential
of DOTPI as a scaffold for the elaboration of therapeutic
radiopharmaceuticals.
MATERIALS AND METHODS
Chemical Synthesis
General
The protected amino acid analogs were purchased
from Bachem (Bubendorf, Switzerland) or Iris Biotech
(Marktredwitz, Germany). All necessary solvents and other
organic reagents were purchased from either, Alfa Aesar
(Karlsruhe, Germany), Sigma-Aldrich (Munich, Germany),
or VWR (Darmstadt, Germany). The DOTPI chelator
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylene(2-
carboxyethylphosphinic acid)]) (Šimecˇek et al., 2013) and
its azide-functionalized derivative DOTPI(azide)4 (Wurzer
et al., 2018) were synthesized, as described previously.
CheMatech (Dijon, France) delivered the NOTA chelator
(1,4,7-triazacyclononane-1,4,7-triacetic acid). The PSMA-
addressing binding motifs (DBCO-KuE and Trz-KuE) were
prepared according to previously published procedures
(Wurzer et al., 2018). Analytical and preparative HPLC were
performed on Shimadzu gradient systems with a SPD-20A
dual wavelength UV/Vis detector (220, 254 nm) with mobile
phase gradients combined of purified water (component
A; from Millipore system) and acetonitrile (component
B; J.T.Baker R©Ultra Gradient HPLC grade, supplemented
with 5% H2O), both containing 0.1% trifluoroacetic acid. A
Nucleosil 100-5 C18 column (125 × 4.6mm) was used for
analytical measurements at a flow rate of 1 mL/min. Preparative
HPLC purification was done using a Multospher 100 RP
18-5µ column (250 × 10mm) at a flow rate of 5 mL/min.
Electrospray ionization (ESI) mass spectra were acquired on
a Varian 500-MS Ion Trap spectrometer (Varian, by Agilent
Technologies).
DOTPI(Chx)4
DOTPI·2 H2O (85.0mg, 105 µmol, 1.0 eq) was dissolved in a
mixture of anhydrous DMSO (420 µL) and DIPEA (320 µL, 1.89
mmol, 20 eq). Then cyclohexylamine (72.9mg, 736 µmol, 7.0 eq)
andHATU (439mg, 1.16mmol, 11 eq) were added in one portion
with stirring. After 1 h at room temperature, the red reaction
mixture was quenched with water (900 µL). The crude product
was purified by size exclusion chromatography (Sephadex G-10
medium, column size: 40 × 3 cm, mobile phase: water, adjusted
to pH 3 with HCl), yielding DOTPI(Chx)4, as a yellow-green
solid (57.7mg, 53µmol, 51%). MW (calcd. for C48H92N8O12P4):
1097.20. HPLC (30–90% B in 15min): tR = 13.2min. 1H-NMR
(300 MHz, D2O, 300K) δ = 1.13–1.36 (m, 20H), 1.57–1.60 (m,
4H), 1.69–1.74 (m, 8H, C(O)-CH2), 1.78–1.87 (m, 16H), 2.37–
2.45 (m, 8H, P-CH2-C), 3.13–3.29 (m, 8H, P-CH2-N), 3.42 (bs,
16H, ring-CH2), 3.52–3.59 (m, 4H, C(O)-NH-CH) ppm. MS
(ESI, positive): m/z = 1098.2 [M+H+], 1119.9 [M+Na+], 549.7
[M+2 H+].
DOTPI(DBCO-KuE)4
DOTPI(azide)4·TFA (2.00mg, 1.65 µmol, 1.0 eq) and DBCO-
KuE (7.13mg, 9.90 µmol, 6.0 eq) were dissolved in a 1:1 mixture
(v/v, 2.2mL) of H2O and tert-butanol and stirred for 12 h
at room temperature. Subsequent purification by preparative
HPLC yielded DOTPI(DBCO-KuE)4·TFA as a colorless solid
(6.02mg, 1.47 µmol, 89%). MW (calcd. for C184H252N40O52P4):
3980.10. HPLC (10–90% B in 15min): tR = 9.2min. MS (ESI,
positive): m/z = 1327.9 [M+3H+], 1335.6 [M+2H++Na+],
1991.4 [M+2H+].
DOTPI(Trz-KuE)4
DOTPI(azide)4 (6.0mg, 4.94 µmol, 1.0 eq), sodium ascorbate
(97.9mg, 494 µmol, 100 eq), and Trz-KuE (11.1mg, 21.7 µmol,
4.4 eq) were dissolved in a 1:1 mixture (v/v, 2mL) of H2O
and tert-butanol. After adding copper(II) acetate monohydrate
(1.18mg, 5.93 µmol, 1.2 eq) dissolved in H2O (250 µL) a
deep blue reaction mixture was formed, which was stirred for
1 h at room temperature. For demetallation, the mixture was
diluted to 6mL with H2O, and NOTA (37.6mg, 124 µmol,
25 eq) was added. After adjusting the pH to 2.2 by adding
1M HCl, the solution was heated to 60◦C for 2 h. Subsequent
preparative HPLC-purification afforded DOTPI(Trz-KuE)4·TFA
as a colorless solid (1.6mg, 0.49 µmol, 10%). MW (calcd. for
C128H216N36O48P4): 3151.24. HPLC (10–60% B in 15min):
tR = 6.9min. MS (ESI, positive):m/z= 1576.6 [M+2H+], 1051.2
[M+3H+], 788.7 [M+4H+].
Equilibrium Studies (Protonation and
Stability Constants)
The chemicals used for the experiments were of the highest
analytical grade. CaCl2, ZnCl2, and CuCl2 solutions were
prepared from solid MCl2 (Aldrich; 99.9%). Concentration
of CaCl2, ZnCl2, and CuCl2 solutions were determined by
complexometric titration with standardized Na2H2EDTA and
xylenol orange (ZnCl2), murexid (CuCl2), and Patton & Reeder
(Ca2+) as indicators. The concentration of the DOTPI(Chx)4,
DOTPI, and EDTA was determined by pH-potentiometric
titration in the presence and absence of a large (40-fold) excess of
CaCl2. All the equilibrium measurements were made at constant
ionic strength maintained by 0.15M NaCl at 25◦C.
For determining the protonation constants of DOTPI(Chx)4
andDOTPI three parallel pH-potentiometric titration weremade
with 0.2M NaOH in 0.002M ligand solutions. The stability and
protonation constants of the CaII and ZnII complexes formed
with DOTPI(Chx)4 and DOTPI ligands have been determined
by direct pH-potentiometric titration made at 1:1 and 2:1 metal
to ligand concentration ratios. (the concentration of ligands was
0.002M). For the calculation of the logKML and logKMLHi values,
the mL base—pH data used were obtained in the pH range
1.7–12.0.
Stability constant of Cu(DOTPI) complex was determined
by spectrophotometry, studying the CuII-DOTPI systems at the
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absorption band of CuII-complex at [H+]= 0.01– 0.2M over the
wavelength range of 400–800 nm. Concentrations of CuII and
DOTPI were 1mM. The H+ concentration in the samples was
adjusted by addition of calculated amounts of 2.0M HCl, while
ionic strength was not constant in these samples. Samples were
kept at 25◦C for a week. Absorbance values were determined
at 9 wavelengths (550, 575, 600, 625, 650, 675, 700, 725, and
750 nm). For calculation of stability and protonation constants of
Cu(DOTPI), molar absorptivities of CuCl2, and Cu(HxL) species
(wherein x = 0, 1, 2 . . . 5) were determined by recording the
spectra of 1.0×10−3, 2.0 × 10−3 and 3.0 × 10−3 M solutions
of CuCl2 and Cu(DOTPI) in the pH range of 1.7–11.7. The
protonation constants of the complexes Cu(DOTPI) and the
stability and protonation constants of the dinuclear Cu2(DOTPI)
complexes were determined by pH-potentiometric titrations,
made at 1:1 and 2:1 metal to ligand concentration ratios.
The stability constant of the Cu(DOTPI(Chx)4) complex
has been determined by spectrophotometry with the use of
competition reactions between DOTPI(Chx)4 and EDTA for the
Cu2+ at pH= 5.0. The concentration of Cu(EDTA) was 0.2mM,
while that of the DOTPI(Chx)4 was varied between 0.1 and
1.0mM (5 samples). The samples were kept at 25◦C for 2 weeks.
The absorbance values and the molar absorptivities of CuCl2,
Cu(DOTPI(Chx)4), and Cu(EDTA) have been determined at
11 wavelength (300, 304, 308, 312, 316, 320, 324, 328, 332,
336, and 340 nm) values between 300 and 340 nm. The molar
absorptivities of CuCl2, Cu(DOTPI(Chx)4), and Cu(EDTA) were
deteremined in 0.05, 0.1, 0.2, 0.3, and 0.4mM solutions. The
absorbance and pH values were determined in the samples
after the equilibrium was reached (the time needed to reach
the equilibria was determined by spectrophotometry). The
spectrophotometric measurements were made with the use
of 1.0 cm cells with a Cary 1E spectrophotometer at 25◦C.
The protonation constants of Cu(DOTPI(Chx)4) complex were
determined by pH-potentiometric titrations at 1:1 metal to ligand
molar ratio.
For pH measurements and titrations, a Metrohm 785
DMP Titrino titration workstation and a Metrohm-6.0233.100
combined electrode were used. Equilibrium measurements were
carried out at a constant ionic strength (0.15M NaCl) in 6mL
samples at 25◦C. The solutions were stirred, and constantly
purged with N2. The titrations were performed in a pH range of
1.7–11.7. KH-phthalate (pH = 4.005) and borax (pH = 9.177)
buffers were used to calibrate the pH meter. For calculation of
[H+] from measured pH values, the method proposed by Irving
et al. was used (Irving et al., 1967). A 0.01M HCl solution was
titrated with the standardized NaOH solution in the presence
of 0.1M NaCl. Differences between the measured (pHread)
and calculated pH (–log[H+]) values were used to obtain the
equilibrium H+ concentration from the pH values, measured
in the titration experiments. For the equilibrium calculations,
the stoichiometric water ionic product (pKw) is also needed to
calculate [H+] values in basic conditions. The VNaOH – pHread
data pairs of the HCl – NaOH titration obtained in the pH range
10.5–12 have been used to calculate the pKw value (pKw = 13.85).
For the calculation of the equilibrium constants the program
PSEQUAD (Zekany and Nagypal, 1985) was used.
Kinetic Studies
The rates of the ligand exchange reactions of Cu(DOTPI)
and Cu(DOTPI(Chx)4) with EDTA ligand were studied by
following the dissociation of Cu(DOTPI) and Cu(DOTPI(Chx)4)
complexes with spectrophotometry at 340 nm, in the pH range
1.7–4.5, in the presence of the 20- and 40-fold excess of EDTA
in order to maintain pseudo-first order kinetic conditions.
Concentrations of Cu(DOTPI) and Cu(DOTPI(Chx)4) were
0.1mM. Kinetic studies were performed with Cary 1E and Cary
100 Bio spectrophotometers, using cell holders thermostated to
25◦C. The pre-thermostated solutions were mixed in tandem
cells (l = 0.874 cm). The ionic strength of the solutions was
kept constant at 0.15M with NaCl. In order to keep the pH
values constant, dichloro-acetic acid (DCA) (pH range 1.5–
2.5), chloro-acetic acid (MCA) (pH range 2.5–3.5) and 1,4-
dimethylpiperazine (DMP) (pH= 3.1–4.5) buffers (0.01M) were
used. Pseudo-first-order rate constants (kd) were calculated by
fitting the absorbance values to the equation
At = (A0 − Ae)e
(−kdt) + Ae (1)
wherein A0, Ae, and At are the absorbance values at the start,
at equilibrium and at the time t of the reaction, respectively.
The calculation of the kinetic parameters were performed
by the fitting of the absorbance–time data pairs with the
Micromath Scientist computer program (version 2.0, Salt Lake
City, UT, USA).
Radiochemistry
For 177Lu-labeling, 10 µL aqueous NH4OAc buffer (1M,
pH = 5.9) were added to 1.0 nmol of the labeling
precursor (1mM in DMSO), 10–40 MBq 177LuCl3 (Specific
Activity > 3,000 GBq/mg, 740 MBq/mL, 0.04M HCl, ITG,
Garching, Germany) and finally filled up to 100 µL with H2O.
The reaction mixture was heated for 30min at 95◦C and the
radiochemical purity was determined using radio-TLC (Silica gel
60, mobile phase: 1:1 mixture of 1M aqueous ammonium acetate
and DMF).
In Vitro and in Vivo Evaluation
Determination of PSMA Affinities
PSMA-expressing LNCaP (human prostate carcinoma) cells were
grown inDubleccomodified Eaglemedium/NutritionMixture F-
12 with Glutamax-I (1:1) (Invitrogen), supplemented with 10%
fetal calf serum and maintained at 37◦C in a humidified 5% CO2
atmosphere. For determination of the PSMA affinity (IC50), cells
were harvested 24 ± 2 h before the experiment and seeded in
24-well plates (1.5 × 105 cells per 1mL well). The competitive
binding assay was carried out as described previously, using the
radioiodinated PSMA ligand (125I-BA)KuE (Weineisen et al.,
2014).
Octanol-Water Distribution Coefficients
Approximately 1 MBq of the 177Lu-labeled tracer was added to
a mixture of 0.5mL phosphate buffered saline (PBS, pH 7.4) and
0.5mL n-octanol in an Eppendorf tube (n = 6). After vigorous
mixing of the suspension for 3min, the vial was centrifuged
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at 11.500 g for 3min for phase separation. 200 µL aliquots
of each phase were withdrawn and measured in a gamma
counter.
Biodistribution
The experiments were carried out in accordance with the
German Animal Welfare Act (Tierschutzgesetz), and were
previously approved by the responsible authority (Regierung
von Oberbayern). The animal model, male CB-17 SCID mice
bearing subcutaneous LNCaP tumor xenografts, were generated
as described before (Weineisen et al., 2014). Approximately 1–4
MBq (varying molar activities; absolute molar amounts of active
compound ranging from 0.11 to 0.15 nmol) of the 177Lu-labeled
PSMA inhibitors were injected into the tail vein of the animals,
which were sacrificed 1 and 24 h post injection (n = 3 per tracer
per time point). Selected organs were removed, weighted and the
activities contained were measured in a γ-counter.
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